Published in final edited form as:

Ann Surg Oncol. 2019 July ; 26(7): 2127–2135. doi:10.1245/s10434-019-07236-8.

Chemoprevention Uptake for Breast Cancer Risk Reduction Varies by Risk Factor

Meghan R. Flanagan, MD, MPH¹, Emily C. Zabor, MS², Michelle Stempel, MPH¹, Debra A. Mangino, DO¹, Monica Morrow, MD¹, and Melissa L. Pilewskie, MD¹

¹Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY

²Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY

Abstract

Background/Objective: The efficacy of chemoprevention for breast cancer risk reduction has been demonstrated in randomized controlled trials; however, use remains low. We sought to determine whether uptake differed by risk factors, and identify reasons for refusal and termination.

Methods: Women seen in a high-risk clinic from 10/2014-6/2017 considered eligible for chemoprevention, (history of LCIS, atypia, family history of breast/ovarian cancer, genetic mutation, or history of chest wall radiation) were retrospectively identified. Breast cancer risk factors were compared among those with and without chemoprevention use, and compliance noted.

Results: 1,506 women were identified, 24% with prior/current chemoprevention use. Women 50 years of age were more likely to use chemoprevention than women <50 (28% versus 11%, $p<0.001$). Chemoprevention use by risk factor ranged from 7% to 40%. Having multiple risk factors did not increase use. Significant variation by risk factor was present among women 50 years ($p<0.001$), but not among women <50 years ($p=0.1$). Among women with a documented discussion regarding chemoprevention (575/1,141), fear of side effects was the most common refusal reason (57/156; 36%). The majority of women (61%) who initiated chemoprevention completed 5 years.

Conclusion: Chemoprevention use among women at increased risk for breast cancer remains low, with more frequent use among women 50 years. These data highlight the need for ongoing educational efforts and counseling, as the majority who begin therapy complete 5 years of use. Given fear of side effects, and low uptake—particularly among women <50 years—alternative risk-reducing strategies are needed.

Corresponding author: Melissa L. Pilewskie, MD, Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, (T) 646 888 4675, (F) 646 888 4920, pilewskm@mskcc.org.

Publisher's Disclaimer: This Author Accepted Manuscript is a PDF file of an unedited peer-reviewed manuscript that has been accepted for publication but has not been copyedited or corrected. The official version of record that is published in the journal is kept up to date and so may therefore differ from this version.

Keywords

chemoprevention; breast cancer; risk reduction; high-risk; atypical lesion; lobular carcinoma in situ; atypical ductal hyperplasia; atypical lobular hyperplasia; family history; tamoxifen; raloxifene; aromatase inhibitor; genetic mutation

INTRODUCTION

As the most commonly diagnosed cancer in American women, breast cancer is a disease of considerable public health importance. Factors that can significantly influence breast cancer risk include family history of breast cancer, personal history of atypical breast lesions or lobular carcinoma in situ (LCIS), mantle field radiation prior to the age of 30 years, and hereditary breast cancer syndromes. The aforementioned risk factors are associated with variable breast cancer risk, ranging from as low as 9% 10-year risk for atypical ductal or lobular hyperplasia to as high as 72% lifetime risk with a BRCA mutation (Table 1).¹⁻¹³

Chemoprevention with selective estrogen receptor modulators (SERMs) or aromatase inhibitors (AIs) is a proven, effective option for breast cancer risk reduction. Randomized controlled trials demonstrated a 38% reduction in overall breast cancer incidence among high-risk women and a 51% reduction in estrogen receptor (ER) positive tumors with use of these agents for 5 years.¹⁴ Based on these trials, the U.S. Food and Drug Administration approved the SERMs tamoxifen and raloxifene for breast cancer chemoprevention among women 35 years of age or older with a 5-year breast cancer risk of 1.67% or higher. The National Comprehensive Cancer Network (NCCN)¹⁵, American Society of Clinical Oncology (ASCO)¹⁶, and United States Preventive Services Task Force (USPSTF)¹⁷ endorse tamoxifen and raloxifene as options to reduce the risk of ER positive breast cancer among high-risk women, and ASCO also supports the use of the AI exemestane in postmenopausal women.

Despite these recommendations, studies have demonstrated low chemoprevention uptake.^{4,18-24} Three large, retrospective studies have demonstrated increased uptake among women with atypical hyperplasia or LCIS compared to those at elevated risk due to family history^{20,21,24}, but to our knowledge there are no studies directly comparing chemoprevention uptake according to a more comprehensive group of major breast cancer risk factors. Therefore, our primary objective was to determine whether chemoprevention uptake varies according to breast cancer risk factor in a large cohort of high-risk women. Reasons for refusal and termination of chemoprevention were also analyzed.

METHODS

We conducted a retrospective study using a prospectively maintained database of women enrolled in the high-risk screening program at Memorial Sloan Kettering Cancer Center (MSK) seen between October 2014 and June 2017. Women were enrolled in the high-risk screening program if they had any of the following risk factors: personal history of atypical breast lesions or LCIS, family history of breast and/or ovarian cancer conferring 20% lifetime risk based on the Tyrer-Cuzick model²⁵, a genetic mutation predisposing to

increased breast cancer risk, or radiation therapy to the chest 30 years of age. Women were excluded from the study if they had a history of invasive breast cancer or ductal carcinoma in situ, or had a risk-reducing bilateral prophylactic mastectomy prior to the study period. Women were individually evaluated and provided with screening and prevention recommendations at the providers' discretion. The MSK Institutional Review Board approved this study.

Each woman was categorized according to high-risk feature. Those with more than 1 high-risk feature were classified into each relevant category, as well as into a separate category of multiple risk factors. Atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH) were grouped together given similar long-term breast cancer risk.^{4,5,7} Additional atypical lesions were classified separately into a group which included atypia NOS, atypia in phyllodes, adenomyoepitheliomatosis with atypia, atypical apocrine adenosis, atypical apocrine metaplasia, atypical papillary lesion, columnar cell changes with atypia, flat epithelial atypia, and cystic hypersecretory hyperplasia with atypia. Genetic mutations were combined into 1 category and included BRCA1, BRCA2, ATM, CDH1, CHECK-2, MSH2/MLN1, PALB2, and MUTYH.

Chemoprevention use was categorized as never versus current or prior use at the most recent clinic visit. Multiple data sources, including physician notes, patient surveys, and electronic prescription reporting were used to identify chemoprevention use and patient characteristics. Clinician notes were used as the primary source of information for all variables, with patient-provided information as a secondary data source. Patient survey links were e-mailed prior to the visit and completed online. Body mass index, tobacco use, medical history, and reasons for not using or terminating chemoprevention were collected. Age 50 years was used as a surrogate for post-menopausal status.

Patient and disease characteristics were summarized using median for continuous variables and frequency for categorical variables. The primary outcome was use of chemoprevention overall, and according to high-risk feature. Between-group comparisons were made using the Kruskal-Wallis test for continuous variables and Fisher's exact or chi-squared test for categorical variables, as appropriate. A p-value <0.05 was considered statistically significant. Secondary outcomes included reasons for lack of chemoprevention uptake and reasons for termination. Given previous literature demonstrating differences in uptake according to menopausal status²²⁻²⁴, we tested for an interaction between risk factor and age, and found a significant interaction with respect to chemoprevention uptake (p<0.001) using a likelihood ratio test. Therefore, we analyzed uptake stratified by age <50 years and 50 years. All statistical analyses were conducted using R software version 3.4.1 (R Core Development Team, Vienna, Austria).

RESULTS

There were 1,506 women included in the study, with a median age of 56 years. Overall, 24% (365/1,506) had current or prior use of chemoprevention (Table 2). The most common risk factors were ADH/ALH (50.3%), followed by LCIS (41.8%) and family history (41.7%). Multiple high-risk features were present for 38.6% of women. The most common genetic

mutations were BRCA1 and BRCA2 (70/78, 89.7%). Current or prior chemoprevention use was significantly higher among women age ≥ 50 years compared to those <50 years (27.9% versus 11.2%, $p<0.001$). Only 8.3% of women who were current smokers had chemoprevention use.

Chemoprevention uptake was lowest among women with ‘other’ atypical lesions (7.5%) (Table 2). Multiple high-risk features, genetic mutation carriers, family history, and LCIS were associated with 27-33% chemoprevention use, whereas among women with ADH/ALH, only 18.6% used chemoprevention. On stratified analysis, there was a significant association between risk factor and use of chemoprevention among women ≥ 50 years ($p<0.001$), but not among women <50 years (Fig. 1).

Among women without current or prior chemoprevention use, half (575/1,141) had a documented discussion regarding chemoprevention at their most recent clinic visit. The most common reason for lack of chemoprevention use was patient refusal (27.1%), with fear of side effects being the most common reason for refusal (Table 3). Nineteen percent (112/575) of women had relative contraindications to chemoprevention. The most common contraindication was child-bearing age, followed by history of thromboembolic disease and active tobacco use.

Among current or prior chemoprevention users, the majority took either tamoxifen or raloxifene, with a minority taking AIs or switching between agents (Table 4). Among current users, 28.9% (52/180) were taking tamoxifen while 68.9% (124/180) were taking raloxifene. Among women with a prior history of chemoprevention use, 60.5% completed at least 5 years of therapy (Table 4). The most common reason for termination secondary to a side effect was development of vaginal bleeding ($n=11$) or thromboembolic disease ($n=8$) (Table 4).

DISCUSSION

In a large contemporary cohort of high-risk women, approximately one-quarter used chemoprevention. These results align with previous studies demonstrating low uptake despite evidence of substantial risk reduction associated with a SERM or an AI in 11 randomized chemoprevention trials.^{14,26-34} Our study of over 1,500 women is one of the largest evaluating chemoprevention use for a comprehensive list of risk factors. Chemoprevention use was greatest among women at highest risk, namely those with genetic mutations, chest wall irradiation, and LCIS.

Chemoprevention use in our cohort was higher than that seen in 2 meta-analyses reporting overall uptake of approximately 15%.^{22,35} When women participating in chemoprevention trials were excluded from these analyses, uptake was even lower—4% in Ropka et al. and 8.7% in Smith et al. Ropka and colleagues described the 4% rate as reflecting realistic uptake in clinical practice. However, 2 of the studies included in the meta-analysis were conducted within 2 years of the publication of NSABP P-1, and low uptake may have reflected both patient and provider reluctance to take or prescribe a preventive medication with meaningful adverse side effects as well as the generally slow diffusion of trial results

into practice.^{36,37} Another study recruited women at elevated 5-year breast cancer risk from 2 healthcare organizations to participate in online education using a decision aid about tamoxifen use.³⁸ The burden of contacting the primary care physician was then placed on the woman, and, not surprisingly, only 0.9% of participants reported taking tamoxifen 3 months after using the decision aid. Patients would have had to be extremely motivated to approach a physician to obtain a prescription, and it has been shown that meeting with and receiving a physician recommendation is critical in improving chemoprevention uptake.^{18,39} Thus, these studies may not reflect contemporary clinical practice in the setting of an academic medical center and/or high-risk screening program. However, even in a patient population motivated enough to be followed in a high-risk screening program, our study indicates that only a minority of women elected to take chemoprevention.

One of the unique aspects of our study was the ability to examine variation in chemoprevention use according to a comprehensive list of risk factors. We found that use largely paralleled level of risk—women with genetic mutations and LCIS had the highest proportions of uptake. Limited data are available regarding the efficacy of tamoxifen risk reduction in BRCA1 and BRCA2 mutation carriers. In a subset of BRCA mutation carriers in NSABP P-1, tamoxifen reduced breast cancer incidence among BRCA2 mutation carriers by 62%, but not among BRCA1 carriers.⁴⁰ Data on the impact of tamoxifen on contralateral risk in BRCA mutation carriers also suggests benefit. Risk reduction was demonstrated in a case-control study evaluating contralateral risk reduction among BRCA mutation carriers. Among BRCA1 and BRCA2 carriers, tamoxifen led to 62% and 37% contralateral breast cancer risk reduction, respectively.⁴¹

Thirty percent of women with LCIS in our cohort used chemoprevention, which is consistent with studies of high-risk women evaluated at either an academic medical center or specialty breast clinic. These studies reported an uptake range of 27%-56% among chemoprevention-eligible women with LCIS.^{4,21,23,24} Use of chemoprevention among women with atypia was similar in a study of 2,938 women with atypical breast lesions at 3 institutions where 41% of women with severe ADH and 33% with ALH took chemoprevention.⁴ Even higher uptake was demonstrated in a large, retrospective, multi-institutional study of 2 state registries, with 66% uptake in a combined group of women with atypia and LCIS.²⁰ In contrast, use of chemoprevention among women with ADH/ALH in our cohort was comparatively low (18%). It is unclear why chemoprevention use is lower among ADH/ALH patients at our institution, particularly in light of the 86% risk reduction demonstrated in NSABP P-1.²⁸ One explanation may be provider bias against the benefit of chemoprevention in women with small-volume atypia based on studies demonstrating a moderate level of risk with only a single focus of atypia.^{4,7}

We found low uptake among young women, which was similar to an uptake rate of 10.6% among 1,279 high-risk women <50 years undergoing active screening in the United Kingdom.⁴² The association of age and chemoprevention use is reflected in several other studies, most recently in a study of 1,719 women diagnosed with atypical hyperplasia, LCIS or DCIS. On multivariate analysis, age was significantly associated with chemoprevention uptake with women <45 years and those >75 years less likely to initiate chemoprevention.²⁴ Tchou et al. found the mean age of high-risk women in their cohort who accepted tamoxifen

was significantly older than those who refused.²³ Reasons for this are likely multi-factorial. The utility of tamoxifen as a breast cancer risk-reduction agent in women <35 years is unknown, and its use is contraindicated in women attempting pregnancy. Additionally, tamoxifen is the only chemoprevention agent available for pre-menopausal women, and, as discussed below, there are multiple concerns about tamoxifen-related side effects. In contrast, post-menopausal women have the option of raloxifene and AIs. In post-menopausal patients, taking raloxifene serves a dual purpose, as it can reduce breast cancer risk but also increase bone density and decrease the risk of vertebral fractures.³⁴

Fear of medication side effects is frequently cited as a reason women decline chemoprevention. In a study of over 600 high-risk women given education with an individually tailored online decision aid, 80% who indicated that they were unlikely to take tamoxifen expressed worry about side effects, and 59% indicated that the benefits were not worth the risk.³⁸ Although the side effects associated with chemoprevention medications are real, they are likely overestimated and misunderstood by high-risk women. In the NSABP P-1 study, the risk of endometrial cancer associated with tamoxifen was only seen in women >50 years, and the absolute increased risk over placebo was 1.4 per 1,000 women.²⁸ Hot flashes are another side effect of concern, but the absolute difference of placebo versus tamoxifen in this trial was only 11%. In a qualitative study of 27 women at risk for breast cancer in a Canadian Family Practice setting, patients were asked about perceived barriers to taking chemoprevention. The most common concern was side effects, but, interestingly, many of the perceived side effects (hair loss, nausea) were those associated with chemotherapy, not chemoprevention.⁴³ Studies involving educational decision aids have unfortunately not had the desired effect of increasing uptake. Five studies with educational interventions in the meta-analysis by Ropka et al had lower uptake rates (4%) than the 8 studies that did not include an intervention (31%).³⁵

There is, however, evidence that physician recommendation can lead to improved uptake. Among a cohort of 175 women who spoke with their primary care doctor following an informational session for NSABP P-1 enrollment, women who reported that their physician advised them to enroll in the trial were 13 times more likely to participate compared to women whose physicians advised them not to participate.³⁹ Bober et al. assessed the importance of physician recommendation on uptake and found that women who received a physician's recommendation, as opposed to simply being informed by the physician of her eligibility, were 47% more likely to take tamoxifen.¹⁸ We are unaware of any studies that focus on differential uptake rates according to type of physician; however, uptake rates are consistently higher in academic settings where there may be more specialists comfortable with discussing the risks and benefits of chemopreventive medications.

Interestingly, we found that over half of women completed their 5-year therapeutic course of chemoprevention once initiated. Coopey et al. showed similar results among women with atypical hyperplasia. They found that only 13% of patients discontinued chemoprevention in less than 1 year, and another 26% by 1-3 years, and that, importantly, 60% took chemoprevention for ≥ 3 years.⁴ These data highlight the importance of counseling high-risk women on chemoprevention eligibility and use, as the majority of women who start chemoprevention will continue for 5 years.

Limitations of this study include those inherent to a retrospective review, including reliance on provider documentation within the electronic medical record. However, multiple sources were utilized, including prescription records, to document chemoprevention use. An additional limitation is that the level of chemoprevention endorsement likely varied among providers and may have contributed to lower levels of uptake among specific groups of women, such as those with atypia. Women who choose to participate in a high-risk screening program at an urban cancer center may represent a motivated population more likely to accept chemoprevention, and our results may not be generalizable to more rural or community practice settings.

Conclusion

Given low chemoprevention uptake among high-risk populations, providers need to focus efforts on counseling women eligible for risk reduction with chemoprevention, improve education on side effects, and encourage a trial of chemoprevention when appropriate, as the majority of women who start chemoprevention complete a 5-year course. Efforts to develop novel therapeutic agents that reduce breast cancer risk while minimizing toxicity are ongoing and may improve chemoprevention uptake.

Acknowledgments

AUTHORS' DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The preparation of this manuscript was funded in part by NIH/NCI Cancer Center Support Grant No. P30 CA008748 to Memorial Sloan Kettering Cancer Center. This study was presented in podium format at the 71st Society of Surgical Oncology Annual Cancer Symposium, March 21-24, 2018, Chicago, IL. Dr. Monica Morrow has received honoraria from Roche and Genomic Health.

REFERENCES

1. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. *Lancet* 2001;358(9291):1389–99. [PubMed: 11705483]
2. Apostolou P, Fostira F. Hereditary breast cancer: the era of new susceptibility genes. *Biomed Res Int* 2013;2013:747318. [PubMed: 23586058]
3. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol* 2007;25(11):1329–33. [PubMed: 17416853]
4. Coopey SB, Mazzola E, Buckley JM, Sharko J, Belli AK, Kim EM, Polubriaginof F, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. *Breast Cancer Res Treat* 2012;136(3):627–33. [PubMed: 23117858]
5. Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA, Maloney SD, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. *J Clin Oncol* 2007;25(19):2671–7. [PubMed: 17563394]
6. Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, Schrader KA, et al. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. *JAMA Oncol* 2015;1(1):23–32. [PubMed: 26182300]
7. Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K. Atypical hyperplasia of the breast--risk assessment and management options. *N Engl J Med* 2015;372(1):78–89. [PubMed: 25551530]
8. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. *Science*. 2003;302(5645):643–6. [PubMed: 14576434]

9. King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, Oskar S, et al. Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. *J Clin Oncol* 2015;33(33):3945–52. [PubMed: 26371145]
10. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. *Jama*. 2017;317(23):2402–16. [PubMed: 28632866]
11. Moskowitz CS, Chou JF, Wolden SL, Bernstein JL, Malhotra J, Novetsky Friedman D, Mubdi NZ, et al. Breast cancer after chest radiation therapy for childhood cancer. *J Clin Oncol* 2014;32(21):2217–23. [PubMed: 24752044]
12. Tung N, Domchek SM, Stadler Z, Nathanson KL, Couch F, Garber JE, Offit K, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. *Nat Rev Clin Oncol* 2016;13(9):581–8. [PubMed: 27296296]
13. van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Steyerberg EW, van Leerdam ME. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. *Am J Gastroenterol* 2010;105(6):1258–64; author reply 65. [PubMed: 20051941]
14. Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. *Lancet* 2013;381(9880):1827–34. [PubMed: 23639488]
15. Bevers TB, Armstrong DK, Arun B, Carlson RW. Breast cancer risk reduction. *National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology* 2016;1.2017.
16. Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2013;31(23):2942–62. [PubMed: 23835710]
17. Moyer VA. Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2013;159(10):698–708. [PubMed: 24061412]
18. Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. *J Clin Oncol* 2004;22(24):4951–7. [PubMed: 15598980]
19. Goldenberg VK, Seewaldt VL, Scott V, Bean GR, Broadwater G, Fabian C, Kimler B, et al. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention. *Cancer Epidemiol Biomarkers Prev* 2007;16(5):1032–4. [PubMed: 17507634]
20. Hermel DJ, Wood ME, Chun J, Rounds T, Sands M, Schwartz S, Schnabel FR. Multi-institutional Evaluation of Women at High Risk of Developing Breast Cancer. *Clin Breast Cancer*. 2017;17(6):427–32. [PubMed: 28539235]
21. Reimers LL, Sivasubramanian PS, Hershman D, Terry MB, Greenlee H, Campbell J, Kalinsky K, et al. Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ. *Breast J*. 2015;21(4):377–86. [PubMed: 25879521]
22. Smith SG, Sestak I, Forster A, Partridge A, Side L, Wolf MS, Horne R, et al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. *Ann Oncol* 2016;27(4):575–90. [PubMed: 26646754]
23. Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M. Acceptance of tamoxifen chemoprevention by physicians and women at risk. *Cancer*. 2004;100(9):1800–6. [PubMed: 15112259]
24. Trivedi MS, Coe AM, Vanegas A, Kukafka R, Crew KD. Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ. *Cancer Prev Res (Phila)*. 2017;10(8):434–41. [PubMed: 28611039]
25. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. *Stat Med* 2004;23(7):1111–30. [PubMed: 15057881]
26. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. *N Engl J Med* 2006;355(2):125–37. [PubMed: 16837676]

27. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. *Jama*. 1999;281(23):2189–97. [PubMed: 10376571]
28. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *J Natl Cancer Inst* 1998;90(18):1371–88. [PubMed: 9747868]
29. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, et al. Exemestane for breast-cancer prevention in postmenopausal women. *N Engl J Med* 2011;364(25):2381–91. [PubMed: 21639806]
30. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. *J Natl Cancer Inst* 2004;96(23):1751–61. [PubMed: 15572757]
31. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. *J Natl Cancer Inst* 2007;99(4):283–90. [PubMed: 17312305]
32. Rivas H, Robles I, Riquelme F, Vivanco M, Jimenez J, Marinkovic B, Uribe M. Magnetic Surgery: Results From First Prospective Clinical Trial in 50 Patients. *Ann Surg* 2018;267(1):88–93. [PubMed: 27759614]
33. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. *Lancet* 1998;352(9122):93–7. [PubMed: 9672273]
34. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *Jama*. 2006;295(23):2727–41. [PubMed: 16754727]
35. Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. *J Clin Oncol* 2010;28(18):3090–5. [PubMed: 20458026]
36. Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. *Ann Surg Oncol* 2001;8(7):580–5. [PubMed: 11508619]
37. Taylor R, Taguchi K. Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. *Ann Fam Med* 2005;3(3):242–7. [PubMed: 15928228]
38. Fagerlin A, Zikmund-Fisher BJ, Nair V, Derry HA, McClure JB, Greene S, Stark A, et al. Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. *Breast Cancer Res Treat* 2010;119(3):613–20. [PubMed: 19908143]
39. Kinney AY, Richards C, Vernon SW, Vogel VG. The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial. *Prev Med* 1998;27(5 Pt 1):713–9. [PubMed: 9808803]
40. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. *Jama*. 2001;286(18):2251–6. [PubMed: 11710890]
41. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. *Lancet* 2000;356(9245):1876–81. [PubMed: 11130383]
42. Donnelly LS, Evans DG, Wiseman J, Fox J, Greenhalgh R, Affen J, Juraskova I, et al. Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. *Br J Cancer*. 2014;110(7):1681–7. [PubMed: 24594998]
43. Heisey R, Pimlott N, Clemons M, Cummings S, Drummond N. Women's views on chemoprevention of breast cancer: qualitative study. *Can Fam Physician*. 2006;52:624–5. [PubMed: 17327893]

Synopsis: Chemoprevention use among high-risk women is low but varies according to patient age and risk factors.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Fig. 1. Chemoprevention uptake according to risk factor stratified by age < 50 years and ≥ 50 years. ADH, atypical ductal hyperplasia; ALH, atypical lobular hyperplasia; LCIS, lobular carcinoma in situ

TABLE 1**Breast cancer risk factors**

Risk Factor	Risk
Family History	Variable based on extent of family history
Lobular carcinoma in situ	21-26% 10 years ⁴
Atypical ductal or lobular hyperplasia	9-25% 10 years ^{4,5,7}
Chest wall irradiation <30 years	30% age 50 ¹¹
Hereditary / Genetic risk	
High penetrance mutations	
BRCA 1	54-72% lifetime ^{3,8,10}
BRCA 2	23-80% lifetime ^{3,8,10}
TP53 (17p1.31)	56-90% lifetime ²
PTEN (10q23.3)	25-50% lifetime ²
STK11 (19p13.3)	32-54% lifetime ^{2,13}
CDH1 (16q22.1)	42-60% lifetime ^{2,6}
Moderate penetrance mutations	
ATM (11q22.3)	15-20% lifetime ²
CHEK2 (truncating)	3.0-fold (90% CI 2.6-3.5) lifetime ¹²
CHEK2 (I157T, missense)	1.6-fold (90% CI 1.42-1.75) lifetime ¹²
NBN (c.657de15)	2.7-fold (90% CI 1.9-3.7) lifetime ¹²
PALB2 (16p12.1)	20-40% lifetime ²

TABLE 2

Patient characteristics

	Overall (n = 1,506) n (%)	Any current/prior use (n = 365) n (%)	No current/prior use (n = 1,141) n (%)	p-value
Demographic				
Median age, years (min, max)	56 (23, 84)	59 (37, 82)	55 (23, 84)	< 0.001
Age at visit, years				< 0.001
<50	331 (22.0)	37 (10.1)	294 (25.8)	
50	1175 (78.0)	328 (89.9)	847 (74.2)	
Smoking status				0.048
Current	24 (1.6)	2 (0.5)	22 (1.9)	
Former	152 (10.1)	48 (13.2)	104 (9.1)	
Never	306 (20.3)	84 (23.0)	222 (19.5)	
Unknown	1024 (68.0)	231 (63.3)	793 (69.5)	
BMI, median (min, max)	24.5 (15.6, 57)	24.3 (15.6, 48.21)	24.7 (16.33, 57)	0.042
Race				0.16
White	1189 (79.0)	309 (84.7)	880 (77.0)	
Black	52 (3.4)	10 (2.7)	42 (3.7)	
Hispanic	50 (3.3)	10 (2.7)	40 (3.5)	
Asian	86 (5.7)	14 (3.8)	72 (6.3)	
Other	4 (0.3)	0 (0)	4 (0.3)	
Unknown	125 (8.3)	22 (6.0)	103 (9.0)	
High-risk feature^a				
Multiple high-risk features				0.06
Yes	581 (38.6)	156 (42.7)	425 (37.2)	
No	925 (61.4)	209 (57.2)	716 (62.8)	
LCIS ^b				< 0.001
Yes	629 (41.8)	190 (52.0)	439 (38.5)	
No	877 (58.2)	175 (48.0)	702 (61.5)	
Family history				0.001
Yes	628 (41.7)	180 (49.3)	448 (39.3)	
No	878 (58.3)	185 (50.7)	693 (60.7)	
ADH or ALH ^b				< 0.001
Yes	758 (50.3)	141 (38.6)	617 (54.1)	
No	748 (49.7)	224 (61.4)	524 (45.9)	
Other atypia ^b				< 0.001
Yes	67 (4.4)	5 (1.4)	62 (5.4)	
No	1439 (95.6)	360 (98.6)	1079 (94.6)	
Genetic mutation ^c				0.06
Yes	78 (5.2)	26 (7.1)	52 (4.5)	
No	1428 (94.8)	339 (92.9)	1089 (94.5)	

	Overall (n = 1,506) n (%)	Any current/prior use (n = 365) n (%)	No current/prior use (n = 1,141) n (%)	p-value
Chest wall irradiation				0.6
Yes	5 (0.3)	2 (0.5)	3 (0.3)	
No	1501 (99.7)	363 (99.5)	1138 (99.7)	

^a Includes risk factor of interest in combination with any other risk factor present for each patient; total percentages add to more than 100%.

^b atypia, NOS (n = 1); atypia in phyllodes (n = 1); adenomyoepitheliomatosis with atypia (n = 1); atypical apocrine adenosis (n = 3); atypical apocrine metaplasia (n = 1); atypical papillary lesion (n = 5); columnar cell changes with atypia (n = 35); flat epithelial atypia (n = 3); cystic hypersecretory hyperplasia with atypia (n = 1)

^c Deleterious gene mutations included ATM (n = 1), BRCA 1 (n = 29), BRCA 2 (n = 41), CDH-1 (n = 1), CHEK2 (n = 1), MSH2/MLN1 (n = 1), p53 (n = 1), MUTYH (n = 1), Not specified (n = 1)

Bold indicates statistical significance, $p < 0.05$.

LCIS, lobular carcinoma in situ; ADH, atypical ductal hyperplasia; ADL, atypical lobular hyperplasia

TABLE 3

Chemoprevention decision among patients with no current or prior use of chemoprevention and documented discussion of chemoprevention at most recent clinic visit

	No current/prior use (n = 575) n(%)
<i>Chemoprevention Decision</i>	
Patient refused	156 (27.1)
Fear of side effects	57
Not interested	12
Will consider when postmenopausal	2
Other/not documented	85
Patient deferred decision	133 (23.1)
Considering bilateral prophylactic mastectomy	11
Other/not documented	122
Contraindication	112 (19.5)
Child-bearing age or actively attempting pregnancy	36
History of thromboembolic disease	29
Currently smoking	22
Currently using hormone replacement therapy	11
Endometrial cancer or vaginal bleeding	6
Undergoing other medical treatments	5
Cataracts	3
Patient accepted, counseling provided	14 (2.4)
Reason for decline not documented	160 (27.8)

TABLE 4

Type of chemopreventive agents used among women with current or prior use, and reasons for termination of chemoprevention among women with prior use

	Current use (n = 180) n (%)	Prior use (n = 185) n (%)
<i>Chemoprevention agent</i>		
Tamoxifen	52 (28.9)	132 (71.4)
Raloxifene	124 (68.9)	46 (24.9)
Multiple agents	0 (0.0)	7 (3.7)
Aromatase inhibitor ^a	4 (2.2)	--
<i>Reasons for termination of chemoprevention among women with prior use</i>		
		Prior use (n = 185) n (%)
Completed therapy ^b		112 (60.5)
Adverse side effects		60 (32.4)
Vaginal bleeding		11
Thromboembolic disease		8
Leg pain		7
Depression/anxiety		6
Other		28
Other/not documented		13 (7.0)

^aIncluded arimidex (n = 2) and exemestane (n = 2)

^bCompleted at least 5 years of therapy